|
|
NEWS
RECALLS
COMPLAINT FORM
SCAM ALERTS
RESOURCES
Small Claims Guide Class Actions Lemon Laws FAQ Newsletters |
Share |
| Automotive Education Employment Electronics Family Finance Health Homeowners Insurance Pets Shopping Travel |
|
|
|
![]() |
Consumer Group Challenges AMA on Drug Ads |
|||||||||||||
|
June 30, 2005
The AMA's announcement failed to acknowledge the fact that drug companies spent five times more on marketing to physicians, including advertising in journals, than they do on advertising to consumers. A large body of research has found that pharmaceutical advertising and marketing to doctors has led to increased prescribing, use and possibly over-use of prescription drugs. "The AMA's feigned concern for the fate of patients targeted by drug advertising makes about as much sense as a pusher enrolling his customers in drug-addicts anonymous," said Jerry Flanagan of the Foundation for Taxpayer and Consumer Rights (FTCR). "Patients and doctors have a right to know how much advertising money the AMA's journal receives from drug companies. Drug companies spend five times as much on marketing to doctors than they do advertising to consumers because they know their profits depend upon whether a doctor is motivated to prescribe the newest blockbuster," Flanagan said. According to the AMA's 2003 tax return, the AMA receives two times more money in advertising dollars than it does from subscriptions. In 2003, the latest data available, the AMA received $41,123,622 from advertising revenue, compared to $17,677,540 from subscription fees. The AMA's advertising revenue accounts for 45 percent of the group's total program revenue. In 2000 (the latest data available) drug companies spent $4.8 billion on "physician detailing," the practice of sending marketers to doctors' offices to encourage doctors to prescribe a company's drugs. In the same year, drug companies spent $2.4 billion on consumer advertising. Total physician promotional spending by drug companies in 2000 was $13.2 billion, including $484 million for journal advertising. In 2004, Pfizer settled a lawsuit for $430 million with the U.S. Attorney General's office that alleged that the company had promoted its anti-convulsant medication, Neurontin, to doctors for "off-label" treatments -- those not approved by the FDA. Report Your Experience
|
|||||||||||||
Back to the top | |
||||||||||||||
Advertisement
|
|
Custom Search
|
||||
|
AUTOMOTIVE Dealers Manufacturers Service Extended Warranties Lemon Laws Recalls Tires Transporters FAMILY Aging Children, Parenting Recalls Dating Education Entertainment Pets Weddings |
FINANCE Annuities Banks Credit Cards Debt Collection Debt Counseling Insurance Investing Loans Mortgages Payday Loans Student Loans Tax Prep HEALTH Doctors Drugs, Pharmacies Health Clubs Hearing Care Hospitals Nursing Homes Nutrition, Diets Vision Care Weight Loss |
HOUSE & HOME Appliances Cookware Furniture Home Improvements Lawn & Garden Movers Pools & Spas Realtors, Rental Agents Recalls Utilities ELECTRONICS Cable TV/DBS Cameras Cell Phones Computers Home Electronics Internet Access Local Phone Service Long Distance VoIP |
SHOPPING In-Home Online Retail Stores Sporting Goods Supermarkets Telemarketers TRAVEL Airlines Bus Lines Car Rental Cruises Hotels Travel Agents Trains RESOURCES Class Actions Complaint Form Small Claims Guide Lemon Laws |
CONSUMER NEWS Latest News Automotive Telecom Financial Health Homeowners Scams Seniors Travel More ... RECALLS Automotive Children's Products Drugs Food Household Products Sporting Goods ABOUT US FAQ Privacy Policy Advertise With Us Newsroom Syndication Terms of Use |
Terms of Use Your use of this site constitutes acceptance of the Terms of Use
Copyright © 2003-2009 ConsumerAffairs.com Inc. All Rights Reserved. The contents of this site may not be republished, reprinted, rewritten or recirculated without written permission. |
|